For the year ending 2025-12-31, GNPX had $6,229,195 increase in cash & cash equivalents over the period.
| Cash Flow | 2025-12-31 |
|---|---|
| Net loss | -16,228,953 |
| Depreciation | 0 |
| Share-based compensation-Excluding Eloc Purchase Agreement | 312,835 |
| Share-based compensation-The2025Eloc Facility | 739,935 |
| Prepaid expenses and other | 50,120 |
| Research and development supplies | -244,630 |
| Accounts payable | -331,226 |
| Other current liabilities | 1,690 |
| Net cash used in operating activities | -15,311,209 |
| Disposals of property and equipment | 0 |
| Reductions to intellectual property | 0 |
| Net cash provided by investing activities | 0 |
| Net proceeds from issuances of common stock | 21,540,404 |
| Net cash provided by financing activities | 21,540,404 |
| Net increase (decrease) in cash and cash equivalents | 6,229,195 |
| Cash and cash equivalents, beginning of year | 1,601,660 |
| Cash and cash equivalents, end of year | 7,830,855 |
Genprex, Inc. (GNPX)
Genprex, Inc. (GNPX)